Bridging antifungal prophylaxis with micafungin in hematopoietic stem cell transplantation: a retrospective analysis

References

• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46:1813–1821. doi:https://doi.org/10.1086/588660.
   PubMed Web of Science ®Google Scholar
• Drgona L, Khachatryan A, Stephens J, et al. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis. 2014;33:7–21. doi:https://doi.org/10.1007/s10096-013-1944-3.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46:150–156. doi:https://doi.org/10.1128/JCM.01901-07.
   PubMed Web of Science ®Google Scholar
• Patil A, Majumdar S. Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol. 2017;69:1635–1660. doi:https://doi.org/10.1111/jphp.12780.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Cornely OA, Donnelly JP, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect. 2012;18(Suppl 7):1–8. doi:https://doi.org/10.1111/1469-0691.12037.
   PubMed Web of Science ®Google Scholar
• Langebrake C, Rohde H, Lellek H, et al. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice. Clin Transpl. 2014;28:286–291.
   PubMed Web of Science ®Google Scholar
• Park S, Kim K, Jang JH, et al. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. J Inf Secur. 2016;73:496–505.
   Google Scholar
• Oyake T, Kowata S, Murai K, et al. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial. Eur J Haematol. 2016;96:602–609.
   PubMed Web of Science ®Google Scholar
• Epstein DJ, Seo SK, Brown JM, et al. Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies. J Antimicrob Chemother. 2018;73:i60–i72.
   PubMed Web of Science ®Google Scholar
• Rieger CT, Ostermann H, Kolb HJ, et al. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients. Ann Hematol. 2008;87:915–922. doi:https://doi.org/10.1007/s00277-008-0534-4.
   PubMed Web of Science ®Google Scholar
• Xu SX, Shen JL, Tang XF, et al. Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis. Eur Rev Med Pharmacol Sci. 2016;20:381–390. PMID: 26875911.
   PubMed Web of Science ®Google Scholar
• Heimann SM, Vehreschild MJ, Meintker L, et al. Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany. Transpl Infect Dis. 2014;16:968–974. doi:https://doi.org/10.1111/tid.12305.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Pappas PG, Young JA, et al. Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. Expert Opin Drug Saf. 2011;10:171–183. doi:https://doi.org/10.1517/14740338.2011.557062.
   PubMed Web of Science ®Google Scholar
• Hiramatsu Y, Maeda Y, Fujii N, et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol. 2008;88:588–595. doi:https://doi.org/10.1007/s12185-008-0196-y.
   PubMed Web of Science ®Google Scholar
• Lee CH, Lin JC, Ho CL, et al. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: a meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0180050.
   PubMed Web of Science ®Google Scholar
• Jeong SH, Kim DY, Jang JH, et al. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study. Ann Hematol. 2016;95:337–344. doi:https://doi.org/10.1007/s00277-015-2545-2.
   PubMed Web of Science ®Google Scholar
• Wang JF, Xue Y, Zhu XB, et al. Effificacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta analysis of RCTs. Eur J Clin Microbiol Infect Dis. 2015;34(4):651–659. doi:https://doi.org/10.1007/s10096-014-2287-4.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Huang YT, Cheng K, et al. Safety and effificacy of intermittent intravenous administration of high-dose micafungin. Clin Infect Dis. 2015;61(Suppl 6):S652–S661. doi:https://doi.org/10.1093/cid/civ818.
   PubMedGoogle Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–1416. doi:https://doi.org/10.1086/422312.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation–a prospective randomized double blind study. J Infect Dis. 1995;171:1545–1552. doi:https://doi.org/10.1093/infdis/171.6.1545.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kurokawa T, Ishiyama K, et al. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. Ann Hematol. 2011;90:1209–1217. doi:https://doi.org/10.1007/s00277-011-1277-1.
   PubMed Web of Science ®Google Scholar
• Park JS, Kim DH, Choi CW, et al. Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases. Acta Haematol. 2010;124:92–97. doi:https://doi.org/10.1159/000315558.
   PubMed Web of Science ®Google Scholar